<DOC>
	<DOC>NCT01668043</DOC>
	<brief_summary>The purpose of this Phase IIa study is to determine whether the antibody (UB-421), targeting the HIV-1 receptor on the CD4 molecule of T-lymphocytes and monocytes, is safe and effective when multiple doses are administered by intravenous infusion to asymptomatic HIV-1 infected adults and to assess pharmacokinetic parameters of the antibody in blood and on cells. The neutralizing activity of UB-421 blocks HIV-1 from binding to its receptor on CD4-positive cells; thus, UB-421 functions as an immunotherapeutic intervention to prevent HIV-1 infection.</brief_summary>
	<brief_title>Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Asymptomatic, treatmentnaive, HIV1 seropositive CD4+ T cell count &gt;350 cells/cubic millimeter HIV1 viral load &gt;5,000 copies/mL Other inclusion criteria apply Active infection requiring immediate therapy (except HIV1) Previous exposure to monoclonal antibody (including UB421) Prior participation in any HIV vaccine trial Use of immunomodulating drugs or systemic chemotherapy Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CD4</keyword>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>